Project leader

 

Prof. Dr. Pirjo Nuutila, MD
Cardiovascular and metabolic research
Phone:+358 2313 1868
Fax:+358 2231 8191

Project staff

Prof. Dr. Olof Solin
Radiochemistry research and development
Phone:+358 2313 2851
Fax:+358 2231 8191

 

Adj. Prof. Dr. Jukka Kemppainen, MD
Nuclear Mecdicine Specialist
Phone:+358 2 313 0196
Fax:-

 

Dr. Marko Seppänen, MD
Nuclear medicine
Phone:+358 2313 0492
Fax+358 2313 2892

 

Dr. Cheng-Bin Yim
Radiopharmaceutical chemistry laboratory
Phone:+358 2313 9116
Fax+358 2231 8191

 

Kirsi Mikkola, MSc
Preclinical research and imaging
Phone:+358 2333 7013
Fax:+358 2 231 8191

 

Paula Lehtiniemi, MSc
Radiopharmaceutical chemistry laboratory
Phone:+358 2 313 2851
Fax:+358 2 231 8191

Institute presentation

About Turku PET Centre

Turku PET Centre is a Finnish national research institute for the use of short-lived positron emitting isotopes in the field of medical research. The Centre was established in 1970s as a joint collaboration between University of Turku, Åbo Akademi University and Turku University Hospital. Turku PET Centre is equipped with cyclotron laboratories, radiochemistry laboratories, preclinical laboratories and the PET imaging laboratory. The Centre has 3 cyclotrons for PET radionuclide production. The radiochemistry laboratory consists of 19 hot cells, with automated synthesis equipment for tracer development and production, and is operating under GMP quality standards. The imaging laboratory consists of 5 dedicated clinical PET scanners, 1 MRI scanner and 1 digital ultrasound device. The preclinical laboratory is equipped with an Inveon Multimodality PET/CT.

The Centre has two major functions, high quality scientific research and diagnostic service for the whole country. The scientific research strategy of the Turku PET Centre involves four major topics: cellular energy metabolism, neurotransmission, preclinical imaging and drug research, and radiochemistry research. The studies are carried out with dedicated physicists and radiochemists, experienced (pre)clinical investigators and other professionals. In addition, the Centre is actively pursuing collaboration with academia and industry to promote and finance its highly interdisciplinary studies.

Contribution within BetaCure

University of Turku (UTU) has developed and will continue optimization of an 18F-labelled exendin-4 analogue towards a clinical grade compound. This 18F-labelled compound may offer the following advantages over the 68Ga-labelled counterpart: improved image quality, lower radiation exposure, especially in the radiosensitive kidney.

Within the work packages UTU is responsible for:
WP2: Optimizing and preclinical evaluation of GLP-1R targeting compounds, especially 18F-exendin-4 for beta cell imaging and its comparison with 68Ga-exendin-4 and 18F-DOPA.
WP3: In close cooperation with WP2, translational testing will be performed for 18F-exendin-4 before clinical trials. GMP production of 18F-exendin-4 is anticipated to occur later during the runtime of the project.
WP4: Clinical evaluation of different exendin-based tracers and 18F-DOPA in humans during therapeutic interventions and therapies.

Print
Top